Stuart Therapeutics has completed patient enrollment in a phase 2 clinical trial of ST-100 for the treatment of dry eye disease.
The drug candidate is based on PolyCol, a synthesized polypeptide tissue reparative platform.
The multicenter, randomized, double-masked, placebo-controlled study will examine the efficacy and safety of the drop in 150 patients with dry eye disease. Two dose levels of ST-100 will be compared with placebo.
“Today’s ‘last-patient-in’ announcement is a major milestone for our company,” Eric Schlumpf, Stuart’s president and CEO, said in